New US-patent for CFS

The current patent covers the test developed by us in cooperation with the Charité Berlin, AG Scheibenbogen, for the quantitative determination of antibodies directed against the ß-adrenergic receptor. A high antibody titer is an indication of the presence of chronic fatigue syndrome (CFS) and thus plays a decisive role in its diagnosis.

swedish study on CFS/ME

Prof. Dr. Jonas Bergquist, University of Uppsala, Sweden, investigated antibodies against adrenergic receptors (a1, a2, b1, b2, b3) and acetylcholine muscarinergic receptors (M1-5) in two Swedish CFS/ME cohorts. For M3R-Ab and M4R-Ab a significant increase in antibody levels was found in CFS/ME patients compared to controls in both cohorts, for b1-adr-R-Ab and b2-adr-R-Ab only in…

Details

CellTrend is a member of the “Network for Pharma Solutions”

The nationwide “Network for Pharma Solutions” (NetPhaSol), consists of 50 competent partners. The 20 research institutions and 30 companies including CellTrend are covering the entire value chain in drug discovery and development.   The “Network for Pharma Solutions” (NetPhaSol) starts campaign for networking and cooperation Are you looking for qualified partner for your project? Are…

Details